Evan J. Anderson, MD

VP Epidemiology
Moderna, Inc.

Disclosure(s): Moderna: Stocks/Bonds (Public Company)

Poster(s):

• (P-146) Individual-level factors associated with acute hospitalization after medically attended acute gastroenteritis and norovirus gastroenteritis in the United States, 2022–2024
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-517) Symptom Severity and Functional Impact of Medically-Attended Influenza, SARS-CoV-2 and RSV Illnesses among Children
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-605) Burden of Hospitalizations Due to Respiratory Syncytial Virus in Adults ≥50 Years of Age and Those with Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-669) Comparing Influenza, SARS-CoV-2, and RSV Illnesses among Adults with and without Chronic Medical Conditions
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-670) Absenteeism due to Viral Acute Respiratory Infections in Children, 2024-2025
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET